The administrative support of UWCCC provides the focal point for achieving """"""""centerness,"""""""" the integration that is the hallmark of a successful Cancer Center. This nebulous attribute is essential in our institution where depth and breadth of science abound. The challenge is to provide the resources and atmosphere that will induce investigators to look past their traditional departmental silos, focus their expertise on cancer and take advantage of the opportunities for collaborative research that are essential for translation from discovery to application. The leaders of the UWCCC are responsible for creating the resources and collegial opportunities that support this philosophy and the staff of the UWCCC are responsible for creating the atmosphere that attracts investigators and maintains their participation. Therefore UWCCC Administration provides the support necessary for the UWCCC to achieve its mission in the forthcoming five years. The three highest goals of the UWCCC, now and for the future, are: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner. The total budget for the administration of the Cancer Center is $3,188,541. This proposal requests support for 14.8% of the administration operating budget. The rest of the operating budget is supported by institutional support and philanthropic dollars.

Public Health Relevance

UWCCC Administration provides the support necessary for the UWCCC to achieve its mission in the forthcoming five years. The three highest goals of the UWCCC are: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762782
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$336,110
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Chute, Colleen; Yang, Xinhai; Meyer, Kristy et al. (2018) Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res 20:66
Farnoodian, Mitra; Sorenson, Christine M; Sheibani, Nader (2018) Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD. J Ophthalmic Vis Res 13:470-486
Nayak, Amruta P; Kapur, Arvinder; Barroilhet, Lisa et al. (2018) Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer. Cancers (Basel) 10:
Litzelman, Kristin; Keller, Abiola O; Tevaarwerk, Amye et al. (2018) Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey. J Gen Intern Med 33:869-876
Gurel, Zafer; Sheibani, Nader (2018) O-Linked ?-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy. Clin Sci (Lond) 132:185-198
Li, Chao; Yu, Jiaquan; Paine, Paxton et al. (2018) Double-exclusive liquid repellency (double-ELR): an enabling technology for rare phenotype analysis. Lab Chip 18:2710-2719
Braun, Rudolf K; Chetty, Chandramu; Balasubramaniam, Vivek et al. (2018) Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem Biophys Res Commun 503:2653-2658
Gangnon, Ronald E; Stout, Natasha K; Alagoz, Oguzhan et al. (2018) Contribution of Breast Cancer to Overall Mortality for US Women. Med Decis Making 38:24S-31S
Turk, Anita A; Wisinski, Kari B (2018) PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498-2506
Liu, Ting; Shi, Changzheng; Duan, Linqi et al. (2018) A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. J Mater Chem B 6:4756-4764

Showing the most recent 10 out of 1528 publications